Cerebroprotein Hydrolysate for Health & Longevity

Created on 10/29/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Opus 5.5 – Audit

Cerebroprotein hydrolysate, a prescription injection made from pig brain, is used for stroke, dementia and head injury but is not approved in the United States. It modestly speeds early stroke recovery and gives small short-term thinking gains in dementia. For healthy adults the evidence is thin; aging findings come from animals only. Trial harms are mostly mild, though allergic reactions and rare seizures are recognized. Product source matters. (Full Review)

Protocol

Manufacturer regimen for cognitive problems
10–30 mL daily, intravenously
Five days weekly for four weeks, two to four cycles yearly; 10 mL gave the best cognitive response in dose-finding
Intramuscular option
Up to 5 mL
Undiluted, injected slowly over three minutes; 5 mL five days weekly was used for post-COVID smell loss
Chinese hydrolysates
Product-specific labels
Not interchangeable with Cerebrolysin milliliter doses because composition and activity differ
Time to effect
Neurological changes after stroke
14 to 21 days
Meta-analysis of stroke rehabilitation trials, manufacturer-co-authored
Cognitive changes in dementia
After four weeks
Dementia meta-analysis, manufacturer-co-authored
Oral N-PEP-12
30 to 90 days
Related oral derivative, tested in healthy adults aged 50–75

Benefits

Contraindications
  • Hypersensitivity to pig-brain peptides or excipients, or prior anaphylaxis to the product
  • Severe renal impairment (no eGFR cutoff stated)
  • Epilepsy or status epilepticus
  • Pregnancy or breastfeeding, outside careful benefit-risk review
  • Active cancer (inferred; no human data)
Key Interactions
  • Antidepressants (sertraline, escitalopram): additive effects
  • MAOIs (phenelzine, selegiline): 30–40 mL with high doses may raise blood pressure
  • Infusion fluids (balanced amino-acid solutions, lipid emulsions, solutions outside pH 5.0–8.0): physically incompatible when mixed in one infusion
  • Rehabilitation and speech therapy: additive
Theoretical (inferred from mechanism)
  • Over-the-counter stimulants and decongestants (caffeine tablets, pseudoephedrine): insomnia, agitation, blood-pressure rise
  • Serotonergic supplements (St John's wort, 5-HTP): agitation, insomnia or excess serotonergic activity
  • Other brain-peptide products (N-PEP-12, Cortexin): duplicated exposure with unknown cumulative effects

Risk & Side Effects

  • Low: Non-fatal serious adverse events in acute stroke; infusion-rate and injection-site reactions; central nervous system activation and low mood; anaphylaxis and hypersensitivity; gastrointestinal upset and appetite loss; headache; blood-pressure changes and other rare reactions
  • Speculative: Contamination from animal tissue or unregulated vials; growth signaling in existing tumors

Monitoring

Marker Target Why
Serum creatinine with eGFR 0.7–1.3 mg/dL in men, 0.6–1.1 mg/dL in women Safety check: severe renal impairment stops use
Blood pressure Below 120/80 mmHg Safety check: rapid infusion and MAOI combinations shift pressure
Cognitive score (MoCA) No established target; change from own baseline Marker expected to change: trials measured cognitive scores
Serum BDNF No established target; change from own baseline Marker expected to change: rose in Alzheimer's patients

Cadence: Baseline before a first course (BDNF optional); blood pressure at the first infusion, then weekly during each four-week course; cognitive testing at the end of each course and again three months later; creatinine before every subsequent course, typically every three to six months

Qualitative Assessment

  • Mental clarity, word-finding and recall in daily tasks
  • Mood stability, especially low mood or irritability in the days after infusions
  • Sleep onset and quality on infusion days
  • Energy and fatigue
  • Dizziness, flushing or headache during or after infusions
  • Injection-site redness, burning or swelling